Please login to the form below

Not currently logged in
Email:
Password:

S-A in informal talks to acquire Genzyme

French drugmaker sanofi-aventis has approached Genzyme regarding a potential acquisition, according to a "reliable" source

French drugmaker sanofi-aventis (S-A) has approached Genzyme regarding a potential acquisition, according to a "reliable" source.

It is thought that S-A started informal talks with Genzyme, the largest maker of medicines for genetic diseases, about two weeks ago. The talks remain at an early stage and issues such as price and management have yet to be discussed.

Acquiring Genzyme would help S-A expand in biotechnology. Earlier this month, sources suggested S-A was planning an acquisition in the US that may be worth $20bn or more, but declined to be specific.

At the time, analysts cited Genzyme as a potential target for a takeover as well as Allegan and Biogen Idec.

Genzyme's current market capitalisation is close to $14bn.

Shares in the biotech firm climbed 21 per cent on the news of the talks, marking the largest stock price increase for Genzyme in more than a decade.

26th July 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics